Immune Pharmaceuticals Inc (fka IMNPQ)

[Investor100]

BIOWORLD TODAY TM@ IMNP
THE DAILY BIOPHARMACEUTICAL NEWS SOURCE
BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS

http://www.bioworld.com/report/BWT062216Immune.pdf

Teper said Immune’s “number one asset” is bertilimumab,
designed to block the infl
ammatory protein eotaxin-1,
enrolling patients in two phase II trials, one for ulcerative
colitis and another in bullous pemphigoid. A third phase II
program in atopic dermatitis (AD) is planned for later this year.
Summit, N.J.-based Celgene Corp. recently put $7.2 billion on
the table for Receptos Inc., of San Diego, to add the highly
touted late-stage S1P modulator ozanimod to its immunology
and infl
ammatory franchise. “We’re not saying we’ll be taken
out,” he said, but bertilimumab “could be partnered with big
pharma or big biotech in the next year or next year and a half.”

Investor 100